๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Incidence and treatment of periampullary duodenal cancer in the U.S. veteran patient population

โœ Scribed by Robert B. Sexe; Terence P. Wade; Katherine S. Virgo; Frank E. Johnson


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
333 KB
Volume
77
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


BACKGROUND.

Because fewer than 1000 cases of primary adenocarcinoma of the duodenum have been reported, earlier series are limited by local referral patterns and the long periods of time needed for retrospective reviews. METHODS. This study reports the outcomes of preiampullary duodenal adenocarcinoma treatments in all hospitals of the Department of Veterans Affairs from 1987 through 1991, using computer and tumor registry records. Patients were grouped by their most aggressive treatment (resection > operative bypass > percutaneous biliary intubation) and survival calculated from the date of this procedure.

RESULTS.

Of 2185 patients with periampullary cancers (1753 pancreatic, 432 other periampullary), 85 were duodenal and thus comprised only 4% of periampullary tumors. Thirty-four duodenal cancers were resected, 44 bypassed, and 7 had biliary intubation, with 30-day mortality rates of 6%, 1896, and 0%. respectively. Mean survival exceeded 1 year in all groups, and resection resulted in a significant increase in mean survival (784 vs. 438 days for nonresection, P = 0.01). The projected 5-year survival rate after resection was 23%. Mean survival after resection of 9 Stage 1-11 cancers was 668 days, but was similar after 5 resections with nodal or other metastases. Similarly, survival did not correlate with cancer stage in 13 palliated patients. CONCLUSIONS. This large study of patients with duodenal cancer provides a unique perspective of disease prevalence and response to surgical treatment. Prolonged survival is common with any treatment, but the longest survivals were after resection. Cancer 1996; 77251-4.


๐Ÿ“œ SIMILAR VOLUMES


Calcium channel blockers, cancer inciden
โœ Karin B. Michels; Bernard A. Rosner; Alexander M. Walker; Meir J. Stampfer; JoAn ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 69 KB ๐Ÿ‘ 1 views

BACKGROUND. Some studies have suggested that the use of calcium channel blockers may increase the risk of cancer. A possible association of the use of calcium channel blockers with cancer incidence and cancer mortality was addressed using data from the Nurses' Health Study. ## METHODS. In this st

Quality of life measurements of speech i
โœ Lucy Hynds Karnell; Gerry F. Funk; J. Bruce Tomblin; Henry T. Hoffman ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 2 views

Background. To employ patient-reported speech outcome data collected on head and neck cancer (HNC) surveys, there is a need to determine (1) the relationship of patient ratings to speech language pathologist (SLP) ratings and (2) whether patients' attitudes toward their speech are an important eleme